Insurers and health care providers had hoped a new class of medicines called biosimilars would keep a check on high drug prices and reduce health spending in America. As it turns out, that may not be the case.
Biosimilars, which are copycats of pricey biologic drugs, are still very new to the U.S. market. Just three such treatments have been approved by the Food and Drug Administration (FDA)—the first one winning clearance in 2014—and there are still open questions surrounding the regulatory pathway for the therapies that present headwinds for drug makers.
